In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Greater weight loss and more diabetes remission were seen among adult women with overweight, obesity, and T2D.

Diabetes mellitus, defined by elevated glycemic markers, is a major risk factor for cardiovascular disease (CVD), which is the most common cause of death among adults with diabetes mellitus, 1 ...

GLP-1 for platform users and 89% accuracy in innovative AI blood glucose prediction; the Company is actively working to ...

The New England Journal of Medicine (NEJM) published results from Novo Nordisk's phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions ...

Research presented at the American Diabetes Association (ADA) annual meeting included a small phase I/II study on stem cell ...

Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously ...

Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce the successful de ...

Acne. Acne is the most common skin condition in the United States, affecting up to 50 million Americans annually. (1) There are different types of acne (blackheads, whiteheads, pimples, acne cysts or ...

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes ...

Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, proudly announces the initial US launch ...

Diabetes is associated with an increased risk of PAD, with an odds ratio ranging from 1.89 to 4.05. 23 In the EUCLID trial, of the 13 885 patients enrolled, 5345 patients (38.5%) had diabetes. 18 It ...